|
1.
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–S66. 2001.PubMed/NCBI
|
|
2.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3.
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar
|
|
4.
|
Reisman DN, Strobeck MW, Betz BL, et al:
Concomitant down-regulation of BRM and BRG1 in human tumor cell
lines: differential effects on RB-mediated growth arrest vs CD44
expression. Oncogene. 21:1196–1207. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Wade PA: Transcriptional control at
regulatory checkpoints by histone deacetylases: molecular
connections between cancer and chromatin. Hum Mol Genet.
10:693–698. 2001. View Article : Google Scholar
|
|
6.
|
Neely KE and Workman JL: The complexity of
chromatin remodeling and its links to cancer. Biochim Biophys Acta.
1603:19–29. 2002.PubMed/NCBI
|
|
7.
|
Klochendler-Yeivin A, Muchardt C and Yaniv
M: SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev.
12:73–79. 2002. View Article : Google Scholar
|
|
8.
|
Davis PK and Brackmann RK: Chromatin
remodeling and cancer. Cancer Biol Ther. 2:22–29. 2003. View Article : Google Scholar
|
|
9.
|
Narlikar GJ, Fan HY and Kingston RE:
Cooperation between complexes that regulate chromatin structure and
transcription. Cell. 108:475–487. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Langst G and Becker PB: Nucleosome
mobilization and positioning by ISWI-containing
chromatin-remodeling factors. J Cell Sci. 114:2561–2568.
2001.PubMed/NCBI
|
|
11.
|
Kingston RE and Narlikar GJ: ATP-dependent
remodeling and acetylation as regulators of chromatin fluidity.
Genes Dev. 13:2339–2352. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Burns LG and Peterson CL: The yeast
SWI-SNF complex facilitates binding of a transcriptional activator
to nucleosomal sites in vivo. Mol Cell Biol. 17:4811–4819.
1997.PubMed/NCBI
|
|
13.
|
Wu C: Chromatin remodeling and the control
of gene expression. J Biol Chem. 272:28171–28174. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Breeden L and Nasmyth K: Cell cycle
control of the yeast HO gene: cis- and trans-acting
regulators. Cell. 48:389–397. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Recht J and Osley MA: Mutations in both
the structured domain and N-terminus of histone H2B bypass the
requirement for Swi-Snf in yeast. EMBO J. 18:229–240. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Phelan ML, Sif S, Narlikar GJ and Kingston
RE: Reconstitution of a core chromatin remodeling complex from
SWI/SNF subunits. Mol Cell. 3:247–253. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Tyler JK and Kadonaga JT: The ‘dark side’
of chromatin remodeling: repressive effects on transcription. Cell.
99:443–446. 1999.
|
|
18.
|
Wang W, Cote J, Xue Y, et al: Purification
and biochemical heterogeneity of the mammalian SWI-SNF complex.
EMBO J. 15:5370–5382. 1996.PubMed/NCBI
|
|
19.
|
Decristofaro MF, Betz BL, Rorie CJ,
Reisman DN, Wang W and Weissman BE: Characterization of SWI/SNF
protein expression in human breast cancer cell lines and other
malignancies. J Cell Physiol. 186:136–145. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
McCarty KS Jr, Miller LS, Cox EB, Konrath
J and McCarty KS Sr: Estrogen receptor analyses. Correlation of
biochemical and immunohistochemical methods using monoclonal
antireceptor antibodies. Arch Pathol Lab Med. 109:716–721.
1985.
|
|
21.
|
Bourgo RJ, Siddiqui H, Fox S, et al:
SWI/SNF deficiency results in aberrant chromatin organization,
mitotic failure, and diminished proliferative capacity. Mol Biol
Cell. 20:3192–3199. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Reisman D, Glaros S and Thompson EA: The
SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Wiegand KC, Shah SP, Al-Agha OM, et al:
ARID1A mutations in endometriosis-associated ovarian carcinomas. N
Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Jones S, Wang TL, Shih Ie M, et al:
Frequent mutations of chromatin remodeling gene ARID1A in ovarian
clear cell carcinoma. Science. 330:228–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Varela I, Tarpey P, Raine K, et al: Exome
sequencing identifies frequent mutation of the SWI/SNF complex gene
PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Weissman B and Knudsen KE: Hijacking the
chromatin remodeling machinery: impact of SWI/SNF perturbations in
cancer. Cancer Res. 69:8223–8230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Roberts CW and Orkin SH: The SWI/SNF
complex - chromatin and cancer. Nat Rev Cancer. 4:133–142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Biegel JA, Kalpana G, Knudsen ES, et al:
The role of INI1 and the SWI/SNF complex in the development of
rhabdoid tumors: meeting summary from the workshop on childhood
atypical teratoid/rhabdoid tumors. Cancer Res. 62:323–328.
2002.PubMed/NCBI
|
|
29.
|
Heinemann V, Boeck S, Hinke A, Labianca R
and Louvet C: Meta-analysis of randomized trials: evaluation of
benefit from gemcitabine-based combination chemotherapy applied in
advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar
|
|
30.
|
El-Rayes BF and Philip PA: A review of
systemic therapy for advanced pancreatic cancer. Clin Adv Hematol
Oncol. 1:430–434. 2003.PubMed/NCBI
|
|
31.
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
32.
|
Glaros S, Cirrincione GM, Muchardt C,
Kleer CG, Michael CW and Reisman D: The reversible epigenetic
silencing of BRM: implications for clinical targeted therapy.
Oncogene. 26:7058–7066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Reisman DN, Sciarrotta J, Wang W,
Funkhouser WK and Weissman BE: Loss of BRG1/BRM in human lung
cancer cell lines and primary lung cancers: correlation with poor
prognosis. Cancer Res. 63:560–566. 2003.PubMed/NCBI
|
|
34.
|
Fukuoka J, Fujii T, Shih JH, et al:
Chromatin remodeling factors and BRM/BRG1 expression as prognostic
indicators in non-small cell lung cancer. Clin Cancer Res.
10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Batsche E, Yaniv M and Muchardt C: The
human SWI/SNF subunit Brm is a regulator of alternative splicing.
Nat Struct Mol Biol. 13:22–29. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Martin TA, Harrison G, Mansel RE and Jiang
WG: The role of the CD44/ezrin complex in cancer metastasis. Crit
Rev Oncol Hematol. 46:165–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Xue Y, Canman JC, Lee CS, et al: The human
SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and
localizes at kinetochores of mitotic chromosomes. Proc Natl Acad
Sci USA. 97:13015–13020. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Maitra A, Wistuba II, Washington C, et al:
High-resolution chromosome 3p allelotyping of breast carcinomas and
precursor lesions demonstrates frequent loss of heterozygosity and
a discontinuous pattern of allele loss. Am J Pathol. 159:119–130.
2001. View Article : Google Scholar
|
|
39.
|
Zabarovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Xia W, Nagase S, Montia AG, et al: BAF180
is a critical regulator of p21 induction and a tumor suppressor
mutated in breast cancer. Cancer Res. 68:1667–1674. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Duns G, Hofstra RM, Sietzema JG, et al:
Targeted exome sequencing in clear cell renal cell carcinoma tumors
suggests aberrant chromatin regulation as a crucial step in ccRCC
development. Hum Mutat. 33:1059–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Nie Z, Xue Y, Yang D, et al: A specificity
and targeting subunit of a human SWI/SNF family-related
chromatin-remodeling complex. Mol Cell Biol. 20:8879–8888. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Sekine I, Sato M, Sunaga N, et al: The
3p21 candidate tumor suppressor gene BAF180 is normally expressed
in human lung cancer. Oncogene. 24:2735–2738. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Wang X, Nagl NG Jr, Flowers S, Zweitzig D,
Dallas PB and Moran E: Expression of p270 (ARID1A), a component of
human SWI/SNF complexes, in human tumors. Int J Cancer.
112:6362004. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Nagl NG Jr, Zweitzig DR, Thimmapaya B,
Beck GR Jr and Moran E: The c-myc gene is a direct target of
mammalian SWI/SNF-related complexes during
differentiation-associated cell cycle arrest. Cancer Res.
66:1289–1293. 2006. View Article : Google Scholar : PubMed/NCBI
|
